Progression in immunotherapy with immune checkpoint inhibitors for advanced gastric cancer / 中国肿瘤生物治疗杂志

ABSTRACT

@# Advanced gastric cancer is one of cancer types with poor prognosis in East Asia and China. Treatment strategies are especially limited in patients with advanced gastric cancer due to the lack of potent efficacy and serious toxicity. In 2017, immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1) have been approved by FDA for treating advanced gastric or gastroesophageal junction cancer (GC/GEJC) as a third-line option. However, immune checkpoint inhibitors have not been used in the first or second-line setting for advanced gastric cancer. Presently, many clinical trials are undergoing to determine the efficacy of combined therapy including checkpoint inhibitor plus chemotherapy, dual combinations with two immune checkpoint inhibitors, to enhance anticancer activity of immune checkpoint inhibitors and expand targeted patients. Furthermore, areas for further study include the development and validation of novel biomarkers to predict patients who are most likely to respond to treatment and characterization of outcomes with immune checkpoint inhibitors in different defined disease subgroups.